ALKERMES | ALKS

Stock Price
29.94
Daily Change
1.02 3.53%
Monthly
12.77%
Yearly
11.47%
Q3 Forecast
29.70

Peers Price Chg Day Year Date
Otsuka Holdings 8,251.00 83.00 1.02% 0.95% Sep/05
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Acadia Pharmaceuticals 25.26 -0.24 -0.94% 57.19% Sep/05
ALKERMES 29.94 1.02 3.53% 11.47% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Malin Corporation 8.00 0 0% 29.03% Sep/01
Merck 84.71 0.66 0.79% -28.14% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05


ALKERMES traded at $29.94 this Friday September 5th, increasing $1.02 or 3.53 percent since the previous trading session. Looking back, over the last four weeks, ALKERMES gained 12.77 percent. Over the last 12 months, its price rose by 11.47 percent. Looking ahead, we forecast ALKERMES to be priced at 29.70 by the end of this quarter and at 29.01 in one year, according to Trading Economics global macro models projections and analysts expectations.

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.